It was in late 2005 that the status of methasterone, in addition to that of four other designer steroids, as an AAS was brought to public awareness by an article published in the Washington Post .  Don Catlin of the UCLA Olympic Laboratory, who conducted the studies, noted methasterone’s similarity to drostanolone. A warning by the FDA was issued soon after to the general public as well as to the distributor, Designer Supplements LLC, for the marketing of this compound.  Methasterone was subsequently added to the World Anti-Doping Agency (WADA) list of prohibited substances in sport.  Despite all of this, methasterone has resurfaced within the supplement industry on several occasions since its banning by WADA.